Looking to publish in Thoracic Cancer? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowThoracic Cancer is an oncology journal that facilitates international collaboration of novel works on basic, translational and applied clinical research in lung, esophageal, mediastinal and breast cancer. Its content spans prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, and translational studies in thoracic cancer, and it welcomes submissions on prevention, treatment, and research relevant to the Asia Pacific region.
Looking to publish in Thoracic Cancer? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Thoracic Cancer accepts the following article types. Click on an article type to view submission instructions.
Original Articles
Reviews
Case Image
Clinical Guidelines
Letters To The Editor
Case Reports
Brief Reports
Recent Publications
Synchronous Surgical Therapy for Bilateral Multiple Pulmonary Nodules: A Single‐Center Analysis of 108 Cases
Huayu He, Jie Bai, Jizheng Tang, Yingze Ning, Wei He, Chutong Lin, Shanwu Ma, Tong Wang, Jingdi Wang, Jintao Song, Keyi Wang, Lili Zheng, Guangliang Qiang
The Relationship Between Pulmonary Spiculation and Central Fibrosis, Along With Other Clinicopathological Features, in Invasive Lung Adenocarcinoma and Its Prognostic Significance
Hanbo Le, Yongkui Zhang, Heping Wang, Yuanyuan Wen, Liyong Qian, Hui He
Prospective Multicenter Observational Study of Anlotinib in Advanced Non‐Small Cell Lung Cancer: Real‐World Evidence From C hina
Jinlin Wang, Youhong Dong, Fengjun Cao, Ruizhi Ran, Yifa Yin, Yinping Li, Yang Fu, Yanhua Xu, Li Kuang, Guiming Chen, Guangqiao Qu, Jun Li, Zhiguo Luo, Qibin Song, Yuan Chen, Xinhua Xu, Tienan Yi, Qian Chu
Single‐Cell Analysis Identifies LYPD6B as a Tumor‐Intrinsic Candidate Associated With Immunotherapy Nonresponse in Breast Cancer
Yifei Wang, Haiwei Quan, Zhiguang Xu, Yixiang Wang, Zhibin Wang
Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non‐Squamous Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study
Keijiro Yamauchi, Kinnosuke Matsumoto, Takayuki Shiroyama, Akihiro Tamiya, Motohiro Tamiya, Akihiro Tsukaguchi, Akito Miyazaki, Kiyohide Komuta, Yasuhiro Mihashi, Hirotomo Machiyama, Kensuke Kanaoka, Tomoki Kuge, Yuhei Kinehara, Nao Shoshihara, Toshie Niki, Soichiro Kato, Yuki Nishikawa, Koji Azuma, Satoshi Tanaka, Akio Osa, Hidekazu Suzuki, Izumi Nagatomo, Junji Uchida, Yoshito Takeda, Atsushi Kumanogoh
Frequently asked questions
How long does it take to publish?
5 days submission to first decision (median).
Reformat to Thoracic Cancer using Livewrite PremiumIs a cover letter required?
A cover letter should be included in the Cover Letter Field of the Research Exchange system. It must confirm the paper has not been published or submitted elsewhere except as a brief abstract, acknowledge that all authors contributed significantly with each author's contribution described, and confirm that all authors agree with the manuscript content.
Reformat to Thoracic Cancer using Livewrite PremiumWhat are the publication costs?
An Article Publication Charge is required upon acceptance. The charge is waived for Editorials, Guidelines, Commentaries, Letter to the Editor, and Invited Reviews.
Reformat to Thoracic Cancer using Livewrite Premium